Novavax

Novavax Presents Data on Updated COVID-19 Vaccine and Progress to Date on its COVID-19-Influenza Combination Vaccine Candidate at World Vaccine Congress 2024

Retrieved on: 
Monday, April 1, 2024
CIC, COVID-19, Immunoglobulin G, Research, WVC, Novavax, NVAX, Messenger, Vaccine

New data from Novavax's ongoing research on its updated XBB.1.5 COVID-19 vaccine in participants who previously received an mRNA vaccine showed robust neutralizing antibody titers for the XBB.1.5 subvariant as well as for the currently circulating JN.1 subvariant.

Key Points: 
  • New data from Novavax's ongoing research on its updated XBB.1.5 COVID-19 vaccine in participants who previously received an mRNA vaccine showed robust neutralizing antibody titers for the XBB.1.5 subvariant as well as for the currently circulating JN.1 subvariant.
  • Data also showed that the vaccine's safety and reactogenicity profile was consistent with its prototype vaccine (NVX-CoV2373).
  • Differences observed in immunoglobulin (IgG) subclass responses and Fcγ-mediated effector functions following mRNA and protein-based COVID-19 vaccinations will be shared.
  • Novavax will also discuss its influenza and CIC vaccine candidates, including a recap of data to date and the timeline for the Phase 3 trial anticipated to start during the second half of 2024.

Novavax to Participate in TD Cowen's 44th Annual Health Care Conference

Retrieved on: 
Thursday, February 29, 2024
NVAX, Novavax, Conference

GAITHERSBURG, Md., Feb. 29, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in TD Cowen's 44th Annual Health Care Conference.

Key Points: 

GAITHERSBURG, Md., Feb. 29, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in TD Cowen's 44th Annual Health Care Conference.

Novavax and Gavi Reach Settlement on 2021 COVID-19 Vaccine Advance Purchase Agreement

Retrieved on: 
Thursday, February 22, 2024
Partnership, Health, COVID-19, Novavax COVID-19 vaccine, Novavax, APA, Public, Vaccine, Pharmaceutical industry

and GENEVA, Feb. 22, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) and Gavi, the Vaccine Alliance (Gavi) today announced they have reached a settlement related to the 2021 Advance Purchase Agreement (APA) for Novavax's prototype COVID-19 vaccine (NVX-CoV2373).

Key Points: 
  • and GENEVA, Feb. 22, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) and Gavi, the Vaccine Alliance (Gavi) today announced they have reached a settlement related to the 2021 Advance Purchase Agreement (APA) for Novavax's prototype COVID-19 vaccine (NVX-CoV2373).
  • This agreement brings the pending arbitration related to the APA to a close.
  • "We look forward to a long-term partnership with Gavi to provide continued access to our protein-based non-mRNA COVID-19 vaccine."
  • It is good for global immunisation, for countries and for healthy manufacturing markets," said David Marlow, Chief Executive Officer (ad int) of Gavi, the Vaccine Alliance.

Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights on February 28, 2024

Retrieved on: 
Tuesday, February 20, 2024
URL, EST, Novavax, Internet service provider

Participants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.

Key Points: 
  • Participants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.
  • Participants can also dial direct to be entered into the call by an Operator and will be prompted to request to join the Novavax, Inc. call.
  • To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled webcast.
  • Available starting at 11:30 a.m. EST, February 28, 2024, until 11:59 p.m. U.S. EST, March 6, 2024

Novavax Makes Changes to Executive Leadership Team to Enhance Focus on Delivery of Strategic Priorities

Retrieved on: 
Friday, November 17, 2023
ID, Corporation, Business development, Chemistry, NVAX, AstraZeneca, Senior, Commercial Operating System, Novavax, Boston Scientific, Suffolk University Law School, Hologic, Vaccine, Vancouver Island University, Rationalization, MedImmune, COVID-19, Long Island University, Business administration, Mallinckrodt, Dell, R, CMC, Infection, Syracuse University, Business, Master of Business Administration, Management, Science, New York University

GAITHERSBURG, Md., Nov. 17, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced changes to its executive leadership team designed to enhance focus on its strategic priorities and continue the evolution of the Company's scale and structure announced last week.

Key Points: 
  • GAITHERSBURG, Md., Nov. 17, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced changes to its executive leadership team designed to enhance focus on its strategic priorities and continue the evolution of the Company's scale and structure announced last week.
  • In this role, Mr. Trizzino will lead the commercial; chemistry, manufacturing and controls or CMC; and regulatory functions.
  • He will continue to serve on the Company's executive leadership team.
  • Mr. Casey will also serve on the Company's executive leadership team.

Novavax to Host Conference Call to Discuss Third Quarter 2023 Financial Results and Operational Highlights on November 9, 2023

Retrieved on: 
Thursday, November 2, 2023
EST, Novavax

Participants will be prompted to request to join the Novavax, Inc. call.

Key Points: 

Participants will be prompted to request to join the Novavax, Inc. call.
To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled webcast.
Available starting at 11:30 a.m. EST, November 9, 2023, until

Novavax Advances Science Supporting Protein-based Vaccine Technology at IDWeek 2023 and World Vaccine Congress Europe 2023

Retrieved on: 
Wednesday, October 11, 2023
COVID-19, Omicron, WVC, NVAX, Vaccine, Development, Research and development, MD, Ageing, Virus, Science, CIC, Messenger, Novavax, EU, Pharmaceutical industry, Research

GAITHERSBURG, Md., Oct. 11, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, will present study findings during two posters sessions at IDWeek 2023 , October 11-15, and three oral presentations at World Vaccine Congress (WVC) Europe 2023, October 16-19.

Key Points: 
  • GAITHERSBURG, Md., Oct. 11, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, will present study findings during two posters sessions at IDWeek 2023 , October 11-15, and three oral presentations at World Vaccine Congress (WVC) Europe 2023, October 16-19.
  • Highlights include clinical data on Novavax's BA.1, BA.5 and bivalent variant vaccines, an evaluation of its prototype COVID-19 vaccine in children aged 6 to 11 years, real-world evidence on adverse events post-COVID vaccination and an update on its COVID-19-Influenza Combination (CIC) vaccine candidate.
  • "We are excited to share the latest clinical data and real-world evidence advancing the science behind our protein-based vaccine technology," said Filip Dubovsky, MD, President of Research and Development, Novavax.
  • "These data will support the expansion of our label and describe characteristics that may help drive vaccine choice."

Novavax Advances Science Supporting Protein-based Vaccine Technology at IDWeek 2023 and World Vaccine Congress Europe 2023

Retrieved on: 
Wednesday, October 11, 2023
COVID-19, Omicron, WVC, NVAX, Vaccine, Development, Research and development, MD, Ageing, Virus, Science, CIC, Messenger, Novavax, EU, Pharmaceutical industry, Research

GAITHERSBURG, Md., Oct. 11, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, will present study findings during two posters sessions at IDWeek 2023 , October 11-15, and three oral presentations at World Vaccine Congress (WVC) Europe 2023, October 16-19.

Key Points: 
  • GAITHERSBURG, Md., Oct. 11, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, will present study findings during two posters sessions at IDWeek 2023 , October 11-15, and three oral presentations at World Vaccine Congress (WVC) Europe 2023, October 16-19.
  • Highlights include clinical data on Novavax's BA.1, BA.5 and bivalent variant vaccines, an evaluation of its prototype COVID-19 vaccine in children aged 6 to 11 years, real-world evidence on adverse events post-COVID vaccination and an update on its COVID-19-Influenza Combination (CIC) vaccine candidate.
  • "We are excited to share the latest clinical data and real-world evidence advancing the science behind our protein-based vaccine technology," said Filip Dubovsky, MD, President of Research and Development, Novavax.
  • "These data will support the expansion of our label and describe characteristics that may help drive vaccine choice."

Novavax Launches Choose to Protect™ Campaign to Educate Public About Importance of Updated COVID Vaccination this Fall

Retrieved on: 
Tuesday, October 10, 2023
Woman, Parent, Health, Partnership, Knowledge, Family, Death, NVAX, Vaccine, COVID, Immunity, Ageing, Education, HealthyWomen, Vaccination, Emergency medicine, Fatigue, Friends, Learning, The Harris Poll, Novavax, Corporate Affairs, Pharmaceutical industry

"COVID vaccine fatigue remains a major obstacle in maintaining immunity and keeping vaccination rates high," said Silvia Taylor, Executive Vice President and Chief Corporate Affairs and Advocacy Officer, Novavax.

Key Points: 
  • "COVID vaccine fatigue remains a major obstacle in maintaining immunity and keeping vaccination rates high," said Silvia Taylor, Executive Vice President and Chief Corporate Affairs and Advocacy Officer, Novavax.
  • Key results from the Choose to Protect survey include:
    While COVID vaccine fatigue has been widely reported,3 adults aged 45+ still recognize the value of vaccines.
  • "Vaccination remains a critical tool to help protect against COVID, especially for the elderly, and those with chronic conditions associated with severe outcomes from COVID," said Dr. Jose Torradas, Emergency Medicine Physician.
  • To learn more about COVID vaccination and the options available, visit www.ChoosetoProtect.com .

Novavax 2023-2024 COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S.

Retrieved on: 
Tuesday, October 3, 2023
EUA, Heart, Pregnancy, Pharmacy, Caregiver, Tell, Arthralgia, Vaccination, Chills, Rite Aid, Infection, Fever, COVID-19, Center for Biologics Evaluation and Research, Coronavirus, Skin, Drug testing welfare recipients, Woman, COVID, Inflammation, Fact sheet, CVS Pharmacy, Government, CDC, Myalgia, Vomiting, Formula, Allergy, Physician, Child, XBB, Korea Disease Control and Prevention Agency, Immune system, USE, VAERS, Nausea, NVAX, European Medicines Agency, Ageing, FDA, Headache, Death, Regulation of tobacco by the U.S. Food and Drug Administration, FD, Food, World Health Organization, Fatigue, Pericarditis, Vaccine, Pharmaceutical industry, Birth control, Medical device, Mobile phone, Novavax COVID-19 vaccine, Hypoesthesia, Adjuvant, Novavax

In the coming days, individuals in the U.S. can go to pharmacies, physicians' offices, clinics and various government entities to receive an updated Novavax vaccine."

Key Points: 
  • In the coming days, individuals in the U.S. can go to pharmacies, physicians' offices, clinics and various government entities to receive an updated Novavax vaccine."
  • What should you mention to your vaccination provider before you or your child get the Novavax COVID-19 Vaccine, Adjuvanted?
  • A person should not get the Novavax COVID-19 Vaccine, Adjuvanted if they had:
    a severe allergic reaction after a previous dose of any Novavax COVID-19 Vaccine, Adjuvanted
    What are the risks of the Novavax COVID-19 Vaccine, Adjuvanted?
  • Women who are vaccinated with the Novavax COVID-19 Vaccine, Adjuvanted during pregnancy are encouraged to enroll in the registry by visiting https://c-viper.pregistry.com .